had greater core positivity, and a higher incidence of clinically significant disease. These results suggest that high risk patients in an inner city setting are also being negatively affected by the implementation of the task force recommendations. Further research is required to determine whether the practice pattern change occurred at the level of PSA screening or rather at patient selection for prostate biopsy. Such research will allow clinicians to provide more granular counseling with regards to PSA screening and prostate biopsies for high risk patients.
INTRODUCTION AND OBJECTIVES:
We examined the association of primary care physician (PCP) length of practice and prostate specific antigen (PSA) screening opinions on the differential effect of the United States Preventative Services Task Force (USPSTF) recommendation against PSA screening in 2012.
METHODS: 54,684 resulted PSA orders at our institution were reviewed from 2010-2015. Tests were excluded if they were performed by a non-PCP, if the provider ordered <4 tests/year, had a practice break >6 months, or if the provider was not employed at the institution for the entire period. Relative proportions of PSA orders per overall unique male ambulatory clinic volume were assessed for 2010-2011 (first period) and 2013-2015 (second period). Changes on a per-provider basis were assessed as a scatterplot, linear regression, and ANOVA. PCPs were surveyed on their attitudes towards the USPSTF recommendation and responses compared to physician seniority and actual PSA ordering habits.
RESULTS: 228,731 unique male non-oncology care patients were assessed. From an initial cohort of 88 PCPs, 22 PCPs met inclusion criteria. Mean time between completion of residency and beginning of period was 16 years (range 2-43). There was a significant inverse relationship (Fig 1) between years since completion of residency and change in the overall proportion of patients who underwent PSA screening, with more senior physicians noted to have a larger relative decline in screening rates after the USPSTF recommendation (R2 ¼ 0.308, p¼0.007). Eighteen PCPs completed a survey on the USPSTF and PSA which revealed no correlation between stated attitudes toward PSA screening and observed practice, however senior PCPs were more likely to claim greater current PSA screening (p¼0.037).
CONCLUSIONS: Greater time since residency completion was significantly associated with screening proportionally fewer men over the period. PCPs' stated opinion on PSA screening did not appear to have a strong influence on actual observed practice. 
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INTRODUCTION AND OBJECTIVES:
Previous studies showed that higher Charlson comorbidity index increased the risk of overall mortality after radical prostatectomy. However, the relationship between comorbidities and prostate cancer-specific outcomes is less well established. While Charlson comorbidity index is a good measurement of health status, it is difficult to capture in retrospective data. Thus, we tested whether a man's overall health status, as reflected by the ASA (American Society of Anesthesiology) score, at the time of radical prostatectomy was associated with more distant prostate cancer-specific outcomes, such as biochemical recurrence (BCR), metastasis, and prostate cancer-specific mortality (PCSM).
METHODS: Data were retrospectively collected on 3102 men who underwent RP between 1992 and 2015 at six Veterans Affairs hospitals in the SEARCH database. Cox proportional hazards analysis was used to test the association between ASA score and BCR, metastasis, all-cause mortality, and PCSM. Models were adjusted for age, race, year of surgery, surgical center, BMI, PSA, biopsy Gleason score, and clinical stage. As 98% of men had a ASA score of 2 or 3, we categorized ASA score as 1-2 vs. 3-4.
RESULTS: There were 1419 (46%) men with ASA score 1-2 and 1683 (54%) men with ASA score 3-4. Men with ASA score 3-4 were older (mean 62 vs. 61), had more recent year of surgery (median 2009 vs. 2007), higher BMI (median 28.6 vs. 27.8), and higher biopsy Gleason score, versus men with ASA score 1-2 (all p<0.001). Men in the higher ASA group had an increased risk of all-cause mortality compared to men in the lower ASA grouping (HR 1.59, p<0.001). There was no increased risk of BCR (p¼0.23), metastasis (p¼0.22), or PCSM (p¼0.83).
CONCLUSIONS: We found that men who underwent radical prostatectomy for prostate cancer with worse baseline health, as reflected by a higher ASA score (3-4 vs. 1-2), had a higher risk of allcause mortality but did not have higher risk of the adverse prostatecancer specific outcomes of BCR, metastasis, or death from prostate cancer. Whether similar results would be obtained if a more granular measure of comorbidity had been used remains to be tested.
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